^
    Back
    Association details:
    Biomarker:KDR overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Immunol
    Title:

    Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer

    Published date:
    10/05/2023
    Excerpt:
    CONTRADICTING EVIDENCE: According to the receiver operating characteristics and Kaplan-Meier curve analyses, patients with high c-MET, EGFR, and VEGFR2 expression at baseline had significantly shorter PFS than those with low expression.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.3389/fimmu.2023.1086479
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2022
    Title:

    EP08.01-054 - ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer

    Published date:
    07/12/2022
    Excerpt:
    During treatment,the expression level of VEGFR2 increased in beneficial patients and decreased in non-beneficial patients, which can be used as a marker for monitoring therapeutic efficacy…The combination of ICIs combined with single-agent chemotherapy shows safety,efficacy, and tolerable adverse events in two or more lines treatment for advanced non-small cell lung cancer.
    Secondary therapy:
    Chemotherapy